CN1277031A - Psoriasis resisting capsule and its preparation - Google Patents
Psoriasis resisting capsule and its preparation Download PDFInfo
- Publication number
- CN1277031A CN1277031A CN 00105176 CN00105176A CN1277031A CN 1277031 A CN1277031 A CN 1277031A CN 00105176 CN00105176 CN 00105176 CN 00105176 A CN00105176 A CN 00105176A CN 1277031 A CN1277031 A CN 1277031A
- Authority
- CN
- China
- Prior art keywords
- radix
- ethanol
- precipitation
- add
- glycoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims description 19
- 201000004681 Psoriasis Diseases 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 11
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 4
- 229940010454 licorice Drugs 0.000 claims abstract description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 96
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 235000019441 ethanol Nutrition 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 27
- 238000001556 precipitation Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- 150000002338 glycosides Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 15
- 229930182482 anthraquinone glycoside Natural products 0.000 claims description 15
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 15
- 229960003321 baicalin Drugs 0.000 claims description 15
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 claims description 14
- 239000004378 Glycyrrhizin Substances 0.000 claims description 14
- 241001071917 Lithospermum Species 0.000 claims description 14
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 claims description 14
- 229940098421 anthraquinone glycoside Drugs 0.000 claims description 14
- 150000008139 anthraquinone glycosides Chemical class 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 14
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 14
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 14
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 14
- 238000012546 transfer Methods 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 238000009413 insulation Methods 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 102000011759 adducin Human genes 0.000 claims description 4
- 108010076723 adducin Proteins 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 244000061458 Solanum melongena Species 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229910000474 mercury oxide Inorganic materials 0.000 claims description 3
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 238000000605 extraction Methods 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 3
- NEZONWMXZKDMKF-UHFFFAOYSA-N C.I. Natural Red 20 Chemical compound C1=CC(O)=C2C(=O)C(C(O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-UHFFFAOYSA-N 0.000 abstract 1
- 235000011030 Lithospermum officinale Nutrition 0.000 abstract 1
- 240000004035 Lithospermum officinale Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000000073 effect on psoriasis Effects 0.000 abstract 1
- 229940100691 oral capsule Drugs 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 230000009471 action Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 150000004056 anthraquinones Chemical class 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010061372 Streptococcal infection Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940046892 lead acetate Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JGQGCJKPBAYEHO-UHFFFAOYSA-N 1-(morpholin-4-ylmethyl)-4-[2-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]ethyl]piperazine-2,6-dione Chemical compound C1C(=O)N(CN2CCOCC2)C(=O)CN1CCN(CC1=O)CC(=O)N1CN1CCOCC1 JGQGCJKPBAYEHO-UHFFFAOYSA-N 0.000 description 2
- GBLIGNUYGOFIKS-UHFFFAOYSA-N 4-[2-(3,5-dioxopiperazin-1-yl)ethyl]piperazine-2,6-dione Chemical compound C1C(=O)NC(=O)CN1CCN1CC(=O)NC(=O)C1 GBLIGNUYGOFIKS-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229930185278 anthraglycoside Natural products 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- OOMYACICIIMLQI-UHFFFAOYSA-L lead(2+);diacetate;hydrate Chemical compound O.[Pb+2].CC([O-])=O.CC([O-])=O OOMYACICIIMLQI-UHFFFAOYSA-L 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- LUIGNPZNIFQHGQ-UHFFFAOYSA-L magnesium methanol diacetate Chemical compound CO.C(C)(=O)[O-].[Mg+2].C(C)(=O)[O-] LUIGNPZNIFQHGQ-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The oral capsule is prepared with five kinds of Chinese medicinal materials including Radix Scutellariae, rhubarb, giant knotwood, gromwell and licorice and through effective component extraction. It is safe, reliable and high in cure rate and has no toxic side effect. It has obvious curative effect on psoriasis of various types, and has also the function of lowering blood lipoid and triglyceride to protect cardiac and cerebral vascular system.
Description
The present invention relates to a kind of psoriasis resisting capsule and preparation method thereof.
Psoriasis is common a kind of dermatosis, and the traditional Chinese medical science thinks that ailment said due to cold or exposure, damp, heat in blood cause.Modern medicine is thought streptococcal infection, and immune dysfunction etc. are relevant.At present, psoriasis is adopted Drug therapy both at home and abroad more, but still has following thorny problem:
(1), Western medicine bimolane, ethyliminum, aminopterin all have certain curative effect.But the bimolane side effect is too big, and it is higher, now inactive that patient takes the back mortality rate; And ethyliminum, aminopterin all damage effect to blood, skeleton.
(2), adrenal cortex hormones drug can control psoriasis, but rebound effect arranged, and makes the state of an illness more serious, causes other Chinese medicine and western medicine all is of no curative effect, and kidney is had side effect.
(3), take traditional Chinese medicine, patent medicine curative effect instability, the mercurous property of the patent medicine that has composition is to all toxic effect of liver, kidney.
Purpose of the present invention just is to solve the psoriatic thorny problem of above Drug therapy, and a kind of damp eliminating of dispeling the wind that has is provided, heat-clearing and toxic substances removing, and to streptococcal infection, viral infection, immune dysfunction etc. all have the Chinese patent medicine of significant curative effect.This medicinal medicine is safe and reliable, short treating period, and the cure rate height is without any toxic and side effects.
Psoriasis resisting capsule of the present invention is to be raw material by Radix Scutellariae, Radix Et Rhizoma Rhei, Rhizoma Polygoni Cuspidati, Radix Arnebiae (Radix Lithospermi), Radix Glycyrrhizae Chinese medicine of the five flavours, is prepared from through effective component extracting, and by every capsules radiacmeter, each component and content are:
Baicalin and the 0.01～0.39g of glycoside unit
Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture 0.01～0.39g
Shikonin 0.01～0.05g
Rhizoma Polygoni Cuspidati extract 0.01～0.05g
The processing step of its preparation method is:
(1), extract drugs
A, Radix Scutellariae is got 3 years plant, and gather spring, and last pot steams 10min and takes out, peeling is dried and is made decoction pieces, decocts three times with the pH7-8 lime water, each decocting time (1.5h, 1h, 0.5h), decocting liquid filters, concentrate, transfer pH1-2 with dilute hydrochloric acid, insulation is at 75 ℃-85 ℃, 30min abandons supernatant, gets precipitation, with distilled water furnishing pasty state, transfer pH7 with 40% sodium hydroxide solution, add 95% ethanol that equates with amount of liquid medicine then, water-bath is warmed to 45 ℃-60 ℃, add 10% dilute hydrochloric acid and transfer pH1-2, insulation 35～45min, the siphon supernatant is got precipitation, be washed till redfree with 95% ethanol and wash out, 50 ℃-60 ℃ are drying to obtain baicalin and glycoside unit;
B, get and deposit Radix Et Rhizoma Rhei decoction piece and licorice piece more than 2 years and break into 20 order coarse powder in 1: 0.5 ratio, moistening with 75% ethanol, in the seepage of packing into the bucket, 70% ethanol that adds 3 times of amounts of crude drug, soak 24h, beginning seepage, 45 of per minutes, effusion filters, add crude drug amount 3% calcium chloride water, stir 5min, use 50% sodium hydroxide solution then, transfer pH8, begin to precipitate, precipitation is placed a week, siphon supernatant, get precipitation 85% washing with alcohol, then 60 ℃ of dry Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture of getting;
C, get Radix Arnebiae (Radix Lithospermi) decoction pieces coarse powder, add 95% ethanol, under 30 ℃ of temperature, soak three times, each 48h, merge lixivium, reclaim ethanol and get extractum, add an amount of distilled water, become blueness with 20% sodium hydroxide solution furnishing purple till, filter filtrate and add dilute hydrochloric acid again, separate out till the aubergine precipitation, get precipitation and be washed till neutrality, 50 ℃ of dry shikonin that get below-60 ℃ with distilled water;
D, get the Rhizoma Polygoni Cuspidati decoction pieces and break into coarse powder, soak three times under 30 ℃ of temperature with 95% ethanol, each 48h merges three times filtrate, reclaim ethanol and get fluid extract, add an amount of distilled water, reflux, reclaim chloroform layer and water layer with chloroform, yellow mercury oxide is separated out in chloroform layer cold preservation, water layer adds the ethyl acetate placement and separates out reddish brown precipitation, gets two kinds of precipitation ethyl alcohol recrystallizations then, promptly gets Rhizoma Polygoni Cuspidati extract;
(2), preparation
Get 0.01～0.39g baicalin and glycoside unit, 0.01～0.39g Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture, 0.01～0.05g shikonin and 0.01～0.05g Rhizoma Polygoni Cuspidati extract, be mixed and made into 80 order medicated powder, by every capsules 0.1～0.5g, incapsulate under the ultraviolet radiation and get final product.
It is raw material that the present invention selects natural plant for use, wherein:
Radix Scutellariae contains baicalin and glycoside unit, and pharmacological action has antiinflammatory, antibiotic, antivirus action, can suppress streptococcal infection.Wherein glycoside unit is the most effective composition of treatment psoriasis, in order to improve curative effect, the present invention reforms original extraction process, character according to Radix Scutellariae, can be dissolved in alkaline aqueous solution, extract glycoside and glycoside unit effective ingredient so make solvent, make solvent with lime water and especially decisive role is played in the extraction of glycoside unit with lime water.
Radix Et Rhizoma Rhei contains the Radix Et Rhizoma Rhei anthraquinone glycoside, also contains various trace elements.Pharmacological action has the broad-spectrum antibacterial action, and antivirus action can produce interferon by excitating organism, and disease resistance enhancemen alleviates endotoxin in the blood.Wherein dissociated anthraquinone is main antipathogenic composition, and clinical proof reduces hyperlipidemia in addition, especially triglyceride reducing and high β-fat egg.Can generate the lower character of complex dissolubility in aqueous solution with Pb++, Al++, Mg++ etc. because of containing Alpha-hydroxy or two vicinal hydroxyl groups in the Radix Et Rhizoma Rhei molecule, so old technology adding lead acetate water solution extracts the anthraquinone glycoside effective constituents.The present invention has reformed old technology lead acetate, and existing technology is with not having deleterious calcium chloride CaCl
2Replace deleterious lead acetate.Because of the technology of extracting glycyrrhizin is the same with Radix Et Rhizoma Rhei technology, extract so be added to together, it is reported that two kinds of medicines are carried together may produce new material and improve curative effect.Licorice ingredient has the effect of the adrenocortical hormone of promotion sample simultaneously, makes solvent with ethanol and can extract effective dissociated anthraquinone and anthraglycosides composition.
Radix Arnebiae (Radix Lithospermi), Rhizoma Polygoni Cuspidati all contain anthraquinones, by chemical property, carry out with different extraction ways.Two kinds of materials of pharmacological action all have antiviral, antibiotic, antiinflammatory action, and it is better that psoriasis is carried out phase pathological changes curative effect.
The qualitative identification reaction of ingredient of the present invention is as follows:
(1) baicalin adds lead acetate test solution 3-6 and drips with distilled water 5ml dissolving, produces the precipitation of Chinese red, contains baicalin and glycoside unit.
(2) get the mixed extract dissolve with ethanol, drip and use developing solvent---toluene on silica gel plate: dichloromethane: glacial acetic acid (6: 3: 1) mixed liquor launches, aloe-emodin RF value 0.22-0.26, emodin RF value 0.28-0.31, chrysophanic acid RF value 0.34-0.37, chrysophanic acid＞0.9RF value, Radix Et Rhizoma Rhei methyl ether＞0.9RF value contains the Radix Et Rhizoma Rhei anthraquinone glycoside.
(3) shikonin is got shikonin and is dissolved in the ethanol, gets 5ml and adds 2% sodium hydroxide NaOH solution 1.5ml, and solution becomes blueness by aubergine, contains shikonin.
(4) get Rhizoma Polygoni Cuspidati extract and be dissolved in the ethanol, get 5ml and add 0.5% magnesium acetate methanol test solution 1ml, can show orange, red, blueness or violet complex, contain emodin.
(5) get Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture, make hemolytic reaction with dissolved in distilled water, hemolytic index 1: 4000.The also available lysate a large amount of bubbles in the boiled back of test tube of packing into produce, and contain glycyrrhizin.
Psoriasis resisting capsule of the present invention shows that through clinical use result following advantage is arranged:
(1), psoriasis resisting capsule is treated psoriasis vulgaris, pustular type psoriasis, erythrodermic psoriasis, psoriasis arthropathica clinically all significant curative effect.Sick time length no matter, general oral anti-tigason capsule, 2～4 of per day for adults, the child reduces by half, and 30 days can take effect.
(2), to select natural plant for use be raw material in the present invention, by science compatibility effective component extracting, extracts new material, improves curative effect.
(3), the present invention treats function and is: blood circulation promoting and blood stasis dispelling, antibiotic, antiinflammatory, antiviral, can enhancing human body immunity etc.Oral without any toxic and side effects, safe and reliable, simultaneously hyperlipidemia, triglyceride all there are the reduction effect, can protect cardiovascular and cerebrovascular vessel.
(4), raw material do not lack, cost is not high, extraction process is easily grasped, but suitability for industrialized production.
(5), this capsule convenient oral absorbs soon, can cover the bitterness and the stink of medicine discomfort.Bioavailability of medicament can improve stability of drug than the tablet height.Remedy the deficiency of other solid dosage forms.
(6), for showing medicine of the present invention, through 180 routine clinical observations to psoriatic therapeutic effect.Male: age 15-56 (average 28 ± 4,37 years old) 96 people, female age 21-45 (average 33 ± 7,14 years old) 84 people.The course of disease 1 year-16 years (average 3,7 ± 6,6 years).Homeliness type 90 examples, sick type 36 examples of erythroderma, arthrosis type 36 examples, pustule type 18 examples.
Therapeutic outcome: clinical recovery 108 examples, effective 66 examples, invalid 6 examples.
Observation index: cure, the erythema pimple disappears, and squama disappears, the disappearance of scratching where it itches; Effectively, the erythema pimple is dwindled thin out, and squama reduces, and scratching where it itches alleviates, and skin lesion disappears more than 50%; Invalid, erythema, pimple do not have obvious change, and squama does not have obvious minimizing, scratch where it itches not have to alleviate, and skin lesion disappears and is less than 50%.The anti-tigason capsule total effective rate of this medicine is more than 95%.
Be illustrated with embodiment below.
Embodiment 1
(1), extract drugs
A, the extraction of baicalin and glycoside unit, get the Radix Scutellariae coarse powder 100g that concocted, add 6 times of amount pH7-8 lime water, boil 1, the two-layer filtered through gauze of 5h, medicinal residues add 4 times of amount lime water again and boil 1h, the lime water that the filtration medicinal residues add 3 times of amounts again boils 0.5h, filters, and merges three times and boils extracting solution, add dilute hydrochloric acid HCl and transfer pH1-2,80 ℃ of insulation 30min, the siphon supernatant adds that with precipitate hot distilled water reconciles into pasty state, add 40% sodium hydroxide NaOH solution adjusting pH7 again and make baicalin and the dissolving of glycoside unit, add equal-volume 95% ethanol, make solution contain the alcohol amount and be about 50%, be heated to 50 ℃ of sucking filtration and get filtrate, filtrate is transferred pH1-2 with 10% dilute hydrochloric acid HCl, 50 ℃ of insulation 30min abandon supernatant, collecting precipitation, sucking filtration, use 95% washing with alcohol, and drain, get baicalin and glycoside unit, yield 3% after 60 ℃ of dryings.
The Radix Et Rhizoma Rhei 100g that deposits more than 2 years is got in the extraction of b, Radix Et Rhizoma Rhei anthraquinone and glycyrrhizin mixture, and Radix Glycyrrhizae 50g breaks into 20 order coarse powder, and is moistening with 75% ethanol, in the seepage of packing into the bucket, adds 70% ethanol of 3 times of amounts of crude drug, soaks 24h, beginning seepage, 45 of per minutes.Get effusion with three layers of filtered through gauze, add crude drug amount 3% calcium chloride CaCl
2Solution 150ml stirs 5min, uses 50% sodium hydroxide NaOH solution then, transfers pH8, places 7 days.The siphon supernatant, the sucking filtration precipitation is used 85% washing with alcohol, and 60 ℃ of temperature dryings get Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture, yield 8% then.
C, shikonin extract, and get Radix Arnebiae (Radix Lithospermi) decoction pieces coarse powder 100g, add 3 times of amount 95% ethanol, soak three times under 30 ℃ of temperature, and each 48h merges three immersion, and three layers of filtered through gauze reclaim ethanol and get extractum, add the 50ml distilled water, stir.Till becoming blueness with 20% sodium hydroxide NaOH solution furnishing purple, three layers of filtered through gauze, filtrate adds dilute hydrochloric acid HCl and separates out precipitation, and precipitation is washed till neutrality with distilled water, dry shikonin below 60 ℃, yield 1%.
D, Rhizoma Polygoni Cuspidati extract, get Rhizoma Polygoni Cuspidati 100g and break into 20 purpose coarse powder,, under 30 ℃ of temperature, soak three times with 3 times of amount 95% ethanol, each 48h, merge immersion, filtered through gauze reclaims ethanol and gets fluid extract, adds the 30ml distilled water, with 10ml chloroform backflow 30min, reclaim chloroform layer and water layer, chloroform layer is put into refrigerator cold-storage 12h, and yellow mercury oxide is arranged, reclaim chloroform, water layer adds ethyl acetate 10ml, and filtrate placement is separated out reddish brown precipitation, gets two kinds of precipitations then, till 95% dissolve with ethanol, sucking filtration reclaims ethanol and gets Rhizoma Polygoni Cuspidati extract, yield 5%.
(2), preparation
Get 0.01g baicalin and glycoside unit, 0.07g Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture, 0.01g shikonin and 0.01g Rhizoma Polygoni Cuspidati extract, be mixed and made into 80 order medicated powder, the 0.1g capsule of packing under the ultraviolet radiation gets final product.
Embodiment 2
(1), extract drugs is with embodiment 1.
(2), preparation
Get 0.12g baicalin and glycoside unit, 0.12g Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture, 0.03g shikonin and 0.03g Rhizoma Polygoni Cuspidati extract, be mixed and made into 80 order medicated powder, the 0.3g capsule of packing under the ultraviolet radiation gets final product.
Embodiment 3
(1), extract drugs is with embodiment 1.
(2), preparation
Get 0.2g baicalin and glycoside unit, 0.2g Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture, 0.05g shikonin and 0.05g Rhizoma Polygoni Cuspidati extract, be mixed and made into 80 order medicated powder, the 0.5g capsule of packing under the ultraviolet radiation gets final product.
Claims (2)
1, a kind of psoriasis resisting capsule is characterized in that this capsule is is raw material by Radix Scutellariae, Radix Et Rhizoma Rhei, Rhizoma Polygoni Cuspidati, Radix Arnebiae (Radix Lithospermi), Radix Glycyrrhizae Chinese medicine of the five flavours, is prepared from through effective component extracting, and by every capsules radiacmeter, each component and content are:
Baicalin and the 0.01～0.39g of glycoside unit
Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture 0.01～0.39g
Shikonin 0.01～0.05g
Rhizoma Polygoni Cuspidati extract 0.01～0.05g
2, a kind of preparation method of psoriasis resisting capsule is characterized in that the processing step of this preparation method is:
(1), extract drugs
A, Radix Scutellariae is got 3 years plant, and gather spring, and last pot steams 10min and takes out, peeling is dried and is made decoction pieces, decocts three times with the pH7-8 lime water, each decocting time (1.5h, 1h, 0.5h), decocting liquid filters, concentrate, transfer pH1-2 with dilute hydrochloric acid, insulation is at 75 ℃-85 ℃, 30min abandons supernatant, gets precipitation, with distilled water furnishing pasty state, transfer pH7 with 40% sodium hydroxide solution, add 95% ethanol that equates with amount of liquid medicine then, water-bath is warmed to 45 ℃-60 ℃, add 10% dilute hydrochloric acid and transfer pH1-2, insulation 35～45min, the siphon supernatant is got precipitation, be washed till redfree with 95% ethanol and wash out, 50 ℃-60 ℃ are drying to obtain baicalin and glycoside unit;
B, get and deposit Radix Et Rhizoma Rhei decoction piece and licorice piece more than 2 years and break into 20 order coarse powder in 1: 0.5 ratio, moistening with 75% ethanol, in the seepage of packing into the bucket, 70% ethanol that adds 3 times of amounts of crude drug, soak 24h, beginning seepage, 45 of per minutes, effusion filters, add crude drug amount 3% calcium chloride water, stir 5min, use 50% sodium hydroxide solution then, transfer pH8, begin to precipitate, precipitation is placed a week, siphon supernatant, get precipitation 85% washing with alcohol, then 60 ℃ of dry Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture of getting;
C, get Radix Arnebiae (Radix Lithospermi) decoction pieces coarse powder, add 95% ethanol, under 30 ℃ of temperature, soak three times, each 48h, merge lixivium, reclaim ethanol and get extractum, add an amount of distilled water, become blueness with 20% sodium hydroxide solution furnishing purple till, filter filtrate and add dilute hydrochloric acid again, separate out till the aubergine precipitation, get precipitation and be washed till neutrality, 50 ℃ of dry shikonin that get below-60 ℃ with distilled water;
D, get the Rhizoma Polygoni Cuspidati decoction pieces and break into coarse powder, soak three times under 30 ℃ of temperature with 95% ethanol, each 48h merges three times filtrate, reclaim ethanol and get fluid extract, add an amount of distilled water, reflux, reclaim chloroform layer and water layer with chloroform, yellow mercury oxide is separated out in chloroform layer cold preservation, water layer adds the ethyl acetate placement and separates out reddish brown precipitation, gets two kinds of precipitation ethyl alcohol recrystallizations then, promptly gets Rhizoma Polygoni Cuspidati extract;
(2), preparation
Get 0.01～0.39g baicalin and glycoside unit, 0.01～0.39g Radix Et Rhizoma Rhei anthraquinone glycoside and glycyrrhizin mixture, 0.01～0.05g shikonin and 0.01～0.05g Rhizoma Polygoni Cuspidati extract, be mixed and made into 80 order medicated powder, by every capsules 0.1～0.5g, incapsulate under the ultraviolet radiation and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00105176A CN1090485C (en) | 2000-04-15 | 2000-04-15 | Psoriasis resisting capsule and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00105176A CN1090485C (en) | 2000-04-15 | 2000-04-15 | Psoriasis resisting capsule and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1277031A true CN1277031A (en) | 2000-12-20 |
| CN1090485C CN1090485C (en) | 2002-09-11 |
Family
ID=4577581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00105176A Expired - Fee Related CN1090485C (en) | 2000-04-15 | 2000-04-15 | Psoriasis resisting capsule and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1090485C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063753A1 (en) * | 2009-11-26 | 2011-06-03 | 桂林商源植物制品有限公司 | Traditional chinese medicine composition for treating oral ulcer and tumor, preparation method and use thereof |
| CN101049341B (en) * | 2007-05-16 | 2011-11-09 | 长春同春堂皮肤病医院 | Chinese traditional medicine preparation for treating psoriasis |
| CN103373913A (en) * | 2012-04-15 | 2013-10-30 | 四川省中医药科学院 | Extraction method of alkannin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044091C (en) * | 1993-09-07 | 1999-07-14 | 刘岐干 | Chinese-medicinal capsule for treatment of psoriasis |
-
2000
- 2000-04-15 CN CN00105176A patent/CN1090485C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049341B (en) * | 2007-05-16 | 2011-11-09 | 长春同春堂皮肤病医院 | Chinese traditional medicine preparation for treating psoriasis |
| WO2011063753A1 (en) * | 2009-11-26 | 2011-06-03 | 桂林商源植物制品有限公司 | Traditional chinese medicine composition for treating oral ulcer and tumor, preparation method and use thereof |
| CN102724991A (en) * | 2009-11-26 | 2012-10-10 | 桂林商源植物制品有限公司 | Traditional Chinese medicine composition for treating oral ulcer and tumor, preparation method and application thereof |
| CN102724991B (en) * | 2009-11-26 | 2014-10-29 | 桂林商源植物制品有限公司 | Traditional Chinese medicine composition for treating oral ulcer and tumor, preparation method and use thereof |
| CN103373913A (en) * | 2012-04-15 | 2013-10-30 | 四川省中医药科学院 | Extraction method of alkannin |
| CN103373913B (en) * | 2012-04-15 | 2015-08-26 | 四川省中医药科学院 | The extracting method of Shikonin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1090485C (en) | 2002-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100335117C (en) | Chinese medicinal lotion for new-borne baby's removing jaundice | |
| CN101596230A (en) | A kind of pharmaceutical composition for the treatment of hepatopathy | |
| CN101195008B (en) | Cattail pollen skin cleaning agent for treating gynecology disease and technique of preparing the same thereof | |
| CN102552769A (en) | Medicine for treating vaginitis and preparation method thereof | |
| CN101850032B (en) | Traditional Chinese medicine composition with anti-tumor effect and preparation method and application thereof | |
| CN1090485C (en) | Psoriasis resisting capsule and its preparation | |
| CN103191167B (en) | Application of eupatorium Chinese | |
| CN106543249A (en) | It is a kind of that the preparation method for preventing and treating hyperuricemia and the medicinal monomer of gout is extracted from Rhizoma Polygoni Cuspidati | |
| CN101564418B (en) | Pharmaceutical composition for treating oral ulcer | |
| CN1259945C (en) | Antipyretic Chinese medicine preparation for child made of bupleurum root and cinnamon twig | |
| CN1104246C (en) | Fumigant lotion for treating anorectal disease and preparing process thereof | |
| CN101041010A (en) | A pharmaceutical composition for treating diabetes and its preparation method | |
| CN1127344C (en) | Oral pill for curing diabetes and its complication | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN102406790A (en) | A Chinese medicinal capsule for treating mammary gland hyperplasia, and its preparation method | |
| CN116763844B (en) | A Chinese medicine composition for treating airway inflammation and preparation method thereof | |
| CN102885915B (en) | Preparation method of controlled-release capsule with functions of detoxifying and diarrhea stopping | |
| CN110075176A (en) | It is a kind of for treating the Chinese medicine composition and application thereof of abdomen pelvic conditions post-operation adhesion | |
| CN1196256A (en) | Medicine for preventing and curing cardiovascular disease, treating prostatic hyperplasia and preparation method thereof | |
| CN1586584A (en) | Sinusitis capsule and its preparing method | |
| CN1839975A (en) | Medicine for treating piles and its preparing process | |
| CN1141113C (en) | Chinese patent medicine for curing peptic ulcer | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method | |
| CN103239522A (en) | Chinese medicine composition for treating diabetes mellitus | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |